FIELD: biotechnology.
SUBSTANCE: invention relates to an aqueous liquid composition which contains: 0.0001–0.006 weight/weight (wt./wt.)% of polypeptide or its pharmaceutically acceptable salt; 0.2–0.4 wt./wt.% of citrate buffer; 0.0005–0.005 wt./wt.% of disodium EDTA; contains 0.001–0.1 wt./wt.% of tyloxapol or does not contain it; tonicity regulator; and purified water in an amount required to achieve 100%, as well as to a kit containing same.
EFFECT: invention is effective for treating dry eye.
25 cl, 2 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| VACCINE AND METHODS FOR DETECTION AND PREVENTION OF FILARIASIS | 2021 |
|
RU2832185C1 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| COMPOSITION AND USE OF ARGININE-DEPLETING AGENTS IN CANCER, OBESITY, METABOLIC DISORDERS AND RELATED COMPLICATIONS AND COMORBIDITIES | 2019 |
|
RU2826185C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| METHODS FOR TREATMENT OF DANON'S DISEASE AND OTHER AUTOPHAGY DISORDERS | 2017 |
|
RU2777571C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
